A monoclonal antibody (MAb) that distinguishes normal from malignant mammary epithelia in tissue or cell lines was generated using a procedure that involved immunetolerization before immunization. Immune-tolerance to two transformed ~11su111patll epithelial cell lines (MCF.7 and MDA.MB.231 cell h e s combined) was induced in neonatal mice withia 24 hr of birth. SuaEssful induction of immunetolerance was determined by an indirect immunohistological method. testing sera from mice against the tolecogen (i.e., the MCF.7 and MDA.MB.231 cell lines). Mice lacking antibodies in their sera against the immune-toletogen wrze subsequently immunized with an extract of normal bteast epithelium. One mouse was selected for hybridoma production based on evidence of serum antibody that showed reactivity with normal mammary epithelial cells (MEC) but not with invasive breast carcinoma cells, as determined by an indirect immunohistological method. Spleen cells ftom the selected mouse were fused with a mouse myeloma cell line to generate MAb. After extensive screening, one MAb was further
Introduction
The use of conventional immunization procedures that utilize crude tissue or cell extracts containing multiple antigens as the immunogens is unlikely to succeed in the isolation of antibodies to weak or low-density antigens that may distinguish normal and neoplastic cells (2,5,6,9,12,14,2 5,26,3 2,3 3) . Such immunization procedures result in the preferential production of antibodies to antigenically strong components that are widely expressed on diverse cell types, both normal and neoplastic (2, 5, 6, 9, 12, 14) . Although monoclonal antibody (MAb) technology permits, in theory, production and selection of antibody specific for a single antigen, even when multiple antigens are present in the immunogen, this goal in practice is rather difficult to achieve. An alternative approach involves Supported in part by University Pathology Associates.
Correspondence to: Dr. S. A. I " , Cancer Rescarch Laboratory, USC School of Medicine, 1303 N. Mission Rd., Los Angeles, CA 90033. studied on the basis of reactivity with normal MEC in tissue and absence of staining of malignant MEC in tissue or tumorithat the antigen detected by the specific antibody was expressed on the apical plasma membrane of normal glandular epithelia that included breast, cervix, colon, lung, pancreas, and stomach, but not on their malignant counterparts in tissue sections. The antigen recognized by the MAb was termed luminal epithelial antigen with an apparent MW of 92 M) (LEA.92 ). This study illustrates the practical wfulness of the immune-tolerizationlimmunization approllch in the generation of antibodies with particular specificity requirements, as in the idendficadon of an antigen that is di&rentiaUy uprcsed in two tissues (e.g., normal and malignant) which otherwise have a multiplicity of antigens in common. (J Hisrochem C y " 42585-591, 1%) WORDS: Immune-tolerizauonlimmunization; Mammary epithelial cell; Monoclonal antibody. genic MEC lines. This test of specificity of reactivity d e d identification and purification of the antigen of choice before immunization, but this is possible only for previously known and wellcharacterized antigens. An alternative would be to induce immunetolerance to widely distributed immunodominant antigens by injection into neonatal mice (22) . Once a state of tolerance to such antigens is established, the immune-tolerized mice can be subsequently immunized with a crude preparation of potential antigens; only those epitopes not included in the original immune-tolerogen will be seen as immunogens. The approach outlined here raises the probability of obtaining antibodies to functionally significant components that may be weak immunogens in mice and, in addition, have not been sufficiently well characterized to permit prior identification or isolation.
We describe the use of an immune-tolerizationlimmunization procedure that resulted in generation of an MAb to a plasma membrane-associated glycoprotein, termed luminal epithelial antigen (LEA.92). IEA.92 is expressed on non-tumorigenic immor-IMAM, ESTEBAN, YOUNG, " T D R talized lines of mammary epithelial cells (MEC) and on normal mammary or extramammary glandular epithelial cells in tissues, but is not detectable on tumorigenic mammary carcinoma cell lines or in most malignant mammary or extramammary glandular epithelial cells in tissues. These findings confirm the ability of the immune-tolerizationlimmunization approach in the generation of antibodies to antigens that may be otherwise overlooked by the immune system in the presence of a multiplicity of immunodominant heterologous antigens expressed by the cells employed in the immunization phase of MAb production.
Materials and Methods

Preparation of Immune-tolerogen/Immunogen
Immune-tolerogen. Established lines of human mammary epithelial cells (MCF.7 and MDA.MB.231) were grown as monolayers as described previously (17) and were washed five times with cold DPBS. The washed cells (10' cells/ml) were lysed with 0.05 M Tris-HC1 buffer, pH 7.5, containing 0.15 M NaCI, 0.5% (v/v) Nonidet P-40 (NP-40), 1 mM phenylmethylsulfonyl fluoride, and 0.5 mM chloromethyl-~-(2-phenyl-l-p-toluene sulfonamide) ethyl ketone (solubilization buffer) on ice for 15 min. The lysates were centrifuged at 35,000 x g and 4°C for 30 min. The supernatant containing NP4O-solubilized materials from the two cell lines were pooled (50%. v/v) and used for tolerization, ELISA, or immunoprecipitation.
Immunogen. Normal breast tissues were obtained from two young women undergoing reduction mammoplasty with no evidence of abnormality. The tissue samples were pooled and minced with a pair of scissors, washed with cold 0.02 M sodium phosphate buffer, pH 7.2, containing 0.15 M NaCl (PBS) and suspended in solubilization buffer without NP-40 (10 g, wh). The suspension was homogenized on ice in a motor-driven Teflon-glass Potter homogenizer. The homogenate was centrifuged at 500 x g and 4'C for 30 min. The supernatant was removed and was successively centrifuged at 35.000 x g and 4'C for 30 min and at 100,000 x g and 4'C for 1 hr. The pellet was recovered and solubilized in the solubilization buffer and centrifuged at 100,000 x g and 4'C for 1 hr. The supernatant containing NP-40-solubilized materials was used for immunization, ELISA, and immunoprecipitation.
Tolerization, Immunization, and Generation of Monoclonal Antibody
The procedure of immune-tolerization and immunization protocol developed previously (22) was applied to this study. Briefly, nine Balb/c mice, within 24 hr after their birth, were injected IP with 100 p1 of immunetolerogen containing 0.5 mg protein extract of each of the two cell lines of human mammary carcinoma cell (MCF.7 and MDA.MB.231 cell lines combined). After 24 hr a second injection of the immune-tolerogen was administered as above. Three weeks later, mice were bled from the tail vein and the sera were screened against the tolerogen. Two methods were employed in parallel, an ELISA using the immune-tolerogen as the target and an immunohistological method using frozen tissue sections of breast tissue that contained both n o d and malignant mammary epithelial cells. Based on these assays, the sera of four mice showed no reactivity to tolerogen. These four mice, at age 3 weeks, were immunized with 0.2 mg protein extract of normal breast tissue (immunogen) in 50% (v/v) complete Freund's adjuvant. Subsequently, two booster injectionswere given weekly as above. Three days after the last booster injection, the mice were again bled and their sera were subjected to screening by ELISA and immunohistological staining methods, this time using both immune-tolerogen and immuno-gen to determine the efficiency of immune-tolerization and immunization procedure. All four mice showed evidence of serum antibodies that reacted to normal mammary epithelium but not to its malignant counterpart in tissue sections.
Spleen cells from the mouse showing the strongest serum reactivity to normal epithelium and absence of binding to malignant mammary epithelium in tissue sections, were fused with mouse myeloma cells (SP2lOAg 14) as described previously (17, 21, 22) . Supernatants from wells shaving hybrid growth were subjected to screening by the ELJSA method as described previously (22) and by an indirect immunohistological method (20) (21) (22) . Hybrids from the positive wells were cloned by limiting dilution (17, 21, 22) . When single clones had grown to about 70% confluence, supematant from each well, exhibiting growth of a single colony, was again assayed as described above. Those hybrids finally selected were subjected to two further cycles of cloning by limiting dilution, a process that appears to favor selection of clones with stable secretion of immunoglobulin.
Preparation and Staining of Cell Lines or Tissue Sections
Cell Lines. The established malignant cell lines employed in this study were obtained from the American Type Culture Collection, Rockville, MD (Gble 1). These cell lines were cultured in DMEM supplemented with 100 U penicillin/ml, 10 pg insulinlml, and 10% (v/v) fetal calf serum. In addition to using the above cell lines, a model system that consists of a normal mammary epithelial cell line, designated 184 (13,34) two immortalized MEC liens (designated 18441, 184BS) established from 184 cells by exposure to benzo(a)pyrene (35) . and a transformed cell line (designated 184AlNl-T-D10) obtained from 184A1 by exposure to oncogenes (11), reflecting various steps of neoplastic transformation, was analyzed for the expression of LEA.92. Detailed characteristics of this model-system have been described elsewhere (11, 13, 34, 35) . Briefly, both the normal (184) and the immortalized (184A1) cells are anchorage-dependent for growth, dependent on epidermal growth factor (EGF) for proliferation, and non-tumorigenic in nude mice (13). In contrast, oncogenically transformed cells, derived from the immortalized cells by transformation using retroviral vectors with the oncogene (v-H-ras) and SV40 large T-antigen, show many different growth characteristics (11). The oncogenically transformed cell line, designated 184AlN4-T-Dl0, is anchorage-independent for growth, independent ofEGF as supplement for proliferation, and is tumorigenic in nude mice (13). Unlike the normal or immortalized mammary epithelial cells, the growth of oncogcnically transformed 184AlN4T-DlO is not inhibited by transformation growth fbCt0r-s (TGFP) (35) . In addition to the a h model, another model system that consists of non-tumorigenic immortalized MEC line (HuMI) and its transformed variant of MuMI-lTul which is tumorigenic in nude mice was also employed in this study (10) .
Tisue sections. Normal and neoplastic tissues were obtained from the surgical pathology files ofthe Los Angeles County-University of Southern California Medical Center. In initial studies, snap-frozen tissues were utilized. Subsequently, formalin-fmd, p d i -e m b e d d e d tissue sections were used. Tissue were sectioned at 5 pm for hematoxylin and eosin or immunostaining.
An indirect unlabeled primary antibody method was used for localizing antigen with the specific antibody as described previously (21.22) . Biotinylated horse anti-mouse immunoglobulin was used as the link between the specific antibody and the avidin-biotin-peroxidase conjugate (ABC). One hundred pl of the primary antibody (10 pg/ml) was applied to tissue sections. Throughout this study, the secondary antibody and ABC reagent were used at a constant concentration, as suggested by the vendor (Vector Laboratories; Burlingame, CA). Visual estimates of intensity of staining were scored as absent (-), weak (I+), moderate (2+), and intense (3+).
%ble 1. Reactivity of anti-LEA.92 antibody with human mammary epithelial cells by an indirect immunocytological staining methoda
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Samples were scorcd for intensity on a scale fromto + + : -, absence of staining; +, weak staining; + +, intense staining.
The cells (2 x 104/well) were plated in 0.5 ml of appropriate medium into each well of tissue-culture chambers (Lab Tck) and were cultured for 72 hr in a humidified atmosphere containing 5% COa. At the end of the incubation period, cells wcre washed with DF'BS, fmd in cold acetone for 30 scc, and stained with anti-LwL.92 antibody with ul indirect immunohistochemical method. The antibody pre-absorbed with the immunogen served U a control.
To account for case-to-case variation in the intensity of staining, normal or neoplastic specimens were evaluated relative to a tissue scction containing normal glandular epithelium. which was scored as 3 + and served as a positive control. Visual estimates of the percentage of cells stained were determined by examining five different and random fields on every tissue section at high magnification ( x 400). The mean of count form the fields examined was used to arrive at the percentage of cells with staining. For each experiment, negative controls were performed to ensure the spccificity of the reaction. These controls included the use of specific antibody after absorption with the immunogen, non-immune m o w serum, or an kclevant MAb ofthe same immunoglobulin dass in lieu ofthe specific MAb.
Comparison of Epitopes
Competitive steric-inference assays were performed by immunocytological techniques to compare the nature of the epitopcs recognized by anti-LEA.92 antibody to those of previously reported antibodies in relation to human mammary epithelial cells. Freshly frozen sections of breast tissue containing normal MEC were incubated fmt with the unlabeled test antibodies that induded EMA (IS), milk-fit globule membrane glycoprotein (MFGM-gp70) (19.23). 18) , human milk-fit globule 1 (HhfFG-1) (1). HMFG-2 (7), epithelium-specific pan-keratin (31), and rcceptor for epidermal growth h o r (30). followed by incubation with a predetermined concentration of biotinylated anti-LEA.92 antibody. The remainder of the staining procedure was as described previously (21.22) . Any change in the intensity of staining with reference to control preparations was recorded.
Metabolic Labeling of Cell Lines
Non-tumorigenic normal (184) The supernatant containing detergent-solubilized materials was subsequently used for immunoprecipitation.
Immunoprecqitation and Analysis of Radiolabeled Cell Extract
The radiolabeled cell lysates (approximately 400 ng of protein containing 5 x 10' cpm) were mixed with 100 pI of either anti-LEA.92 antibody (0.1 mglml). For each experiment, negative controls were performed to ensure the specificity of the reaction. These controls included the use of specific antibody after absorption with the immunogen (1 mg protcinlml). nonimmune mouse se", or an MAb (IgG11) of an krehant specificity in lieu of the specific MAb. The mixtures were incubated overnight at 4'C.
After incubation, a 1OO-kl suspension of Sepharose 4B conjugated to goat anti-mouse immunoglobulins was added to each reaction mixture. The samples were incubated for a further period of 1 hr and centrifuged at 5000
x g for 10 min. After removal of the supernatant by aspintion, the pellet was washed five times with 0.05 M E-HCI b&r, pH 7.5, containing 0.15 M NaCI, 1.0% (wlv) ovalbumin, and 0.2% (vlv) W O to remm any nonspecifically bound radioactivity. No radioactivity was detected in the supematant of the f i i wash.
The materials immunoprecipitated with and-LEA.92 antibody were subsequently analyzed under non-reducing (in the absence of 2-mercaptoethanol) or reducing (in the presence of 2-mcrcaptoethanol) conditions by SDS-PAGE in 7.5% polyacrylamide slab gels by the method of Lacmmli (24) . Finally, gels were fixed, stained. destained. treated with "Enhance" (New England Nuclear; Boston, MA), dried on Whatman #3 MM fdtcr paper, and the radioactive components visualized by fluorography (17). malignant mammary epithelium in tissue sections were utilized for generating MAb. The hybrids were repeatedly subcloned until one clone, secreting consistently high levels of MAb with binding activity to normal cells ( Figure 1A ) but with lack of reactivity against invasive carcinoma cells in breast tissue sections ( Figure 1B) , was finally selected for further study. The antibody was termed antiluminal epithelial antigen (LEA.92) to indicate its reactivity and the apparent MW of the target antigen. Double-immunodiffusion studies with rabbit antibodies to a subclass of murine immunoglobulin revealed that anti-LEA.92 antibody is an IgGl with K-light chain. Anti-LEA.92 antibody was purified and a portion of the purified antibody was also labeled with biotin as described previously (17, 22) .
Results
Generation of Monoclonal Antibodies
Immunocytological Localization of LEA. 92 in CeLl Lines
Expression of LEA.92 was demonstrated on the plasma membrane of both normal and immortalized MEC lines (Figure 2 ). Specificity was confirmed in that antibody pre-adsorbed with the immunogen tailed to react with the target cells. Furthermore, negative controls in which the antibody was replaced by an irrelevant MAb of the same immunoglobulin class or by non-immune mouse serum also showed no reactivity. In contrast, the oncogenically transformed HMEC (194AlN4-T-DlO or HuMI-TIiul) and established tumor cell lines of breast (Table I) , cervix, colon, kidney, liver, lung, pancreas, stomach, and thyroid, as well as melanoma and hematopoietic cell lines, showed no detectable LEA.92 expression.
Immunohistological Localization of LEA.92
In normal breast tissues, L.EA.92 was expressed predominantly on the apical plasma membrane of luminal epithelial cells lining the ducts or lobules ( Figure 1A) . In benign breast diseases, such as After immunostaining, the cells were counterstained with Mayer's hematoxylin. The rest of the immunostaining procedure was as described in the text. The antibody shows strong reactivity predominantly with the cell surface. Bar = 30 pm. fibroadenoma or hyperplasia, as in normal breast, expression of LEA.92 was seen. The pattern or specificity of reactivity of anti-LEA.92 antibody was identical in frozen and in formalin-fEed tissue sections, leading to a preference for the latter based on superior morphology and availability of a wide range of tissue specimens. In contrast, invasive ductal or lobular mammary carcinoma cells failed to exhibit detectable expression of LEA.92 ( Figure 1B ; Table  2 ). In extramammary tissue, a characteristically similar pattern of LEA.92 expression was observed in various normal luminal epithelial cells lining the ducts or lobules that included cervix, colon, lung, pancreas, and stomach ('liable 2). As in breast, the expression of LEA.92 was detectable on the apical plasma membrane of normal cells of the above organs, whereas the corresponding malignant epithelia in tissue specimens were consistently negative. 
Discussion
The hybridoma technique, in principle, allows the generation and selection of MAb with specificity for a specific epitope even when immunogens containing multiple antigens (epitopes) are used. Despite incorporation into the selection criteria of intensive and elaborate screening procedures, obtaining antibody of a desired specificity is often extremely difficult to achieve when extracts of whole cells are used as the immunogen (2, 5, 6, 9, 12, 14) . Conventional immunization methods utilizing extracts of tissues or cells preferentially elicit the generation of antibodies to immunogenically dominant antigens, most of which are associated with the cytoskeleton or the cell surface mucins and are shared among many different cell types, or the production of antibodies to heterolo-Comparison was made between epitopes recognized by anti-LEA.92 antibody and antibodies to EMA, MFGM-gp70, MFGM-gpl55, HMFG-1, HMFG-2, epithelium-specific pan-keratin, and receptor for epidermal growth factor. The immunoblocking assays showed that the antigenic binding site for anti-LEA.92 antibody was not gous antigens. As a result, antibodies to immunogenically weak antigens, which can be specific to a cell type, are likely to be generated less often or at lower titer, and hence are difficult to detect during screening. Likewise, diverse attempts to obtain antibodies to tumor-associated antigens have resulted in generation of a few antibodies to immunogenically strong antigens that are shared between normal cells and their malignant counterparts (2, 5, 6, 9, 12, 14, 25, 26, 32, 33) .
In the present study, an approach of immune-tolerization with breast tumor cells and immunization with their normal counterparts was taken in an attempt to develop MAb with specificity for antigens present on normal cells but absent in invasive or metastatic mammary carcinoma cells. To reduce the probability of obtaining antibodies to common immunodominant antigens present in normal or malignant mammary epithelial cells (MEC), immunetolerance to these antigens was induced in neonatal mice before subsequent immunization with normal epithelial cells. Achievement of immune-tolerance was evaluated by ELISA techniques using extract of tolerogen (malignant epithelium) and by h u n o h i s t ological methods. Immune-tolerance was established in four of nine mice after a 3-week course of toleritation. These four mice achieved tolerance, attesting to the validity of the immune-tolerizationlimmunization procedure. Owing to an absence of immune response in four mice that maintained a state of immune-tolerance, the tolerogen was injected into naive mice that exhibited production of antibodies to the tolerogen, suggesting that the tolerogen preparation was immunogenic in mice (unpublished observation). Four of nine mice that maintained immune-tolerance were significantly smaller than the remaining five mice, indicating a difference in the rate of their development. The significance of physical development to immune-tolerance has not been reported. However, neonatal immune-tolerization of rodent is said to have an adverse effect on the B-cells of the developing immune system (29, 36) and also the helper T-cells (28), resulting in their possible clonal abortion and suppression that may lead to the induction of immunetolerance (27) . The precise mechanisms ofthe induction ofimmunetolerance in neonatal rodent are not known.
The immune-tolerized mice were subsequently immunized with extract of normal breast tissue (immunogen). Evidence of production of antibody was sought by contrasting absence of reactivity for malignant mammary epithelium and positive reactivity with normal mammary epithelium by immunohistological or ELISA methods. Finally, spleen cells from the mouse showing strongest discrimination between normal and malignant MEC were utilized as the fusion partner for generation of hybridomas that yielded a number ofdones which produced MAb. An MAb with the desired properties was selected for the subsequent study.
The analysis of immunoprecipitates resulting from the incubation of the antibody and [3H]-leucine or [3H]-galactosamine by SDS-PAGE revealed a component with the same size, clearly suggesting that the component is glycosylated. Furthermore, the pattem of migration of the components under both chemically nonreducing conditions remained unchanged, suggesting the absence of disulfide bonds within the molecule. In addition, the characterization ofcpitope recognized by anti-LEA.92 antibody revealed that it is distinct from those of other epithelium-associated antigens that have been reported previously (1,7,15,16,18,19,23,30,31) .
The patterns and specificity of LEA.92 expression on cells in tissue sections mirrored those in cell lines, as the glycoprotein was expressed on MEC in normal mammary or extramammary tissues but, in contrast, malignant mammary or extramammary epithelial cells in tissues failed to exhibit a detectable amount of LEA.92.
A detailed study using a large number of cases is warranted to map more precisely LEA.92 expression during the progression of breast oncogenesis by incorporating tissue specimens from patients with various types of dysplasia and in situ carcinomas of breast. It remains to be determined whether such differential expression, if observed in a large series, has biologic or prognostic significance.
LEA.92 was consistently detectable on normal or immortalized MEC lines that were non-tumorigenic in nude mice. In contrast, LEA.92 was undetectable on oncogenically transformed and established lines of mammary carcinoma cell lines that were tumorigenic, suggesting an inverse-correlation between the expression of LEA.92 and the development of tumorigenicity in malignant MEC lines. The possibility of elimination of the epitope recognized by the antibody can be attributed to a change in splicing or posttranslational modifications of LEA.92. The possible variation in the sequence can be determined by the technique of polymerase chain reaction (PCR) once the cDNA sequence encoding LEA.92 is determined.
Finally, the recognition of oncogenes that induce immortalization of cells from breast tissue or milk has resulted in the establishment of cell lines representing, at least morphologically, two different cell types (4, 8) . This phenomenon can be attributed to the complexity of cells in mammary gland. For example, luminal epithelial cells are said to functionally differentiate by mostly unknown mechanisms from cells located in the basal layer (3). The study of the mechanism of diffcrentiation is paramount to understanding of in vitro breast oncogenesis. Therefore, anti-LEA.92 antibody, which specifically recognizes an antigen on the apical plasma membrane of luminal epithelial cells, can be used as a probe to distinguish luminal from non-luminal epithelial cells of mammary and possibly extramammary tissues at an early stage of primary culture. Furthermore, the mechanism of inducing in vitro basal layer cells into functionally differentiated luminal epithelial cells might be monitored by the induction of LEA.92 expression. 
